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An essential aspect of normal brain function is the bidirectional interaction and
communication between neurons and neighbouring glial cells. To this end, the
brain has evolved ligand–receptor partnerships that facilitate crosstalk between
different cell types. The chemokine, fractalkine (FKN), is expressed on neuronal
cells, and its receptor, CX3CR1, is predominantly expressed on microglia. This
review focuses on several important functional roles for FKN/CX3CR1 in both
health and disease of the central nervous system. It has been posited that FKN
is involved in microglial infiltration of the brain during development. Microglia,
in turn, are implicated in the developmental synaptic pruning that occurs
during brain maturation. The abundance of FKN on mature hippocampal neur-
ons suggests a homeostatic non-inflammatory role in mechanisms of learning
and memory. There is substantial evidence describing a role for FKN in hippo-
campal synaptic plasticity. FKN, on the one hand, appears to prevent excess
microglial activation in the absence of injurywhile promoting activation ofmicro-
glia and astrocytes during inflammatory episodes. Thus, FKN appears to be
neuroprotective in some settings, whereas it contributes to neuronal damage in
others. Many progressive neuroinflammatory disorders that are associated with
increased microglial activation, such as Alzheimer’s disease, show disruption
of the FKN/CX3CR1 communication system. Thus, targeting CX3CR1 receptor
hyperactivation with specific antagonists in such neuroinflammatory conditions
may eventually lead to novel neurotherapeutics.2. Introduction
In recent years, there has been an explosion in our understanding of how
non-neuronal cells play crucial roles in many functions of the central nervous
system (CNS). At present, these non-neuronal cell types are broadly categorized
into (i) astrocytes, (ii) radial glia, (iii) oligodendrocytes, (iv) ependymal cells and
(v) microglia. There exists further subcategories for each group and, more
recently, NG2-positive glia are widely considered a distinct cell type [1–7].
The concept that the brain houses both neurons and ‘neuroglia’ was introduced
in 1856 by the neuropathologist, Rudolf Virchow [8]. However, others that came
after are credited with refining the classification of the various non-neuronal cell
types present in the brain. Between them, Golgi [9], Andriezen [10] and Cajal
[11] defined several distinct types of glial cells in the CNS. It was not until
1919, however, that Rio-Hortega, a student of Cajal, described microglia by
labelling them with a modified silver carbonate stain [12]. Microglia are funda-
mentally distinct from other brain cells, being derived from primitive peripheral
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Microglia are the resident phagocytic cells in the brain,
taking part in immune-mediated defence mechanisms and
clearing damaged cell debris [15,16]. Previously, it was thought
that microglia, in their resting state, are relatively quiescent.
More recent work suggests that microglia are constantly
active and surveying their surroundings [17,18]. Microglia
are now implicated in synapse pruning, during both develop-
ment and throughout adulthood, and therefore play a role in
regulating homeostatic synaptic plasticity [19].
Togetherwith astrocytes, microglia can release neuromodu-
latory chemicals that influence neuronal firing and intracellular
signalling.When first described, astrocytes were seenmerely as
structural scaffolding to support and cushion neuronal cells
within the brain, in essence, to fill the gaps between neurons
[20]. However, that idea was quickly dismissed by Golgi who
suggested that the function of astrocytes may be to provide
nutrients for neurons. Cajal, however, did not fully agree with
either of these explanations [8]. Recent evidence suggests
that astrocytes serve as much more than a nutrient supply or
supportive scaffolding to protect neural networks [21]. Asmen-
tioned, they release factors that modulate neurotransmission
[22–24] and more recently have been suggested to possess
their own repertoire of gliotransmitters [25–31]. The important
roles played by glial cells in normal and pathological brain
functioning are growing, and a more complete picture of
neuron–glia interactions is beginning to emerge.
Glial cells are now accepted as key neuromodulators at
every stage of development and adulthood and, therefore,
must possess multiple mechanisms of communication with
neuronal cell types. One method in which neurons and micro-
glia are thought to communicate with one another is through
neuronally expressed fractalkine (FKN; also known as
CX3CL1 in the new chemokine nomenclature) [32]. FKN is
expressed at the cell membrane of many neurons and binds
to and activates CX3CR1 receptors onmicroglia [33]. Therefore,
neuronally derived FKN can induce effects in microglia that
may, in response, release neuromodulators that act back
upon the same neuron and others in close proximity [34].
This neuron–glia crosstalk is the basis of this review, and we
focus on the role played by FKN and CX3CR1 receptors in
health and disease of the CNS.3. Fractalkine: structure and cellular
localization
Chemokines are abundantly expressed in many areas of the
brain and spinal cord during development [35]. They regulate
essential functions, including cell migration and differentiation
[36]. Chemokines play diverse functions in the CNS during
development, and later, throughout adulthood, they continue
to mediate cell–cell communication [37] and regulate key
functions such as neuroprotection following injury [33,38–45].
There are four distinct subfamilies of chemokines (a, b, g
and d); categorized based on their amino acid structure. Most
chemokines (except the g subfamily) contain four conserved
cysteine residues that form disulfide bonds to produce the
defining chemokine domain. FKN is the only member of the
d subfamily of chemokines containing three amino acids (X3)
separating the first two cysteine (C) residues [35]. It is also unu-
sual in that it appears to bind only one receptor, the seven
transmembrane Gi protein-coupled CX3CR1; many otherchemokine members exhibit more promiscuous binding
activity than FKN. The full-length molecule is larger than
most other chemokines, containing approximately 373 amino
acid residues compared with the more common 70–80 amino
acid size range. FKN exists in two distinct forms. The first is
an approximately 95 kDa full-length membrane-bound form
that possesses a 76-amino acid N-terminal chemokine
domain, a 241-amino acid glycosylated mucin-like stalk, an
18-amino acid hydrophobic transmembrane region and a 37-
amino acid intracellular C-terminal domain. The second is an
approximately 70 kDa soluble form that contains theN-terminal
chemokine domain. The extracellular chemokine domain of
FKN is proteolytically cleaved from the membrane-bound frac-
tion by the lysosomal cysteine protease, cathepsin S and
members of the ADAM (a disintegrin and metalloproteinase)
family such as ADAM-10 and ADAM-17 (also known as
TACE: tumour necrosis factor (TNF)-a-converting enzyme)
[46–49]. The chemokine domain of FKN remains as a monomer
in solution, as opposed to forming dimers which is more
common for other chemokines [50]. The soluble chemokine
domain of FKN, when cleaved, can act as a signalling molecule
and can bind microglial-expressed CX3CR1 receptors [51],
whereas its membrane-tethered mucin stalk can serve as a cell
adhesion molecule [52] for microglia and infiltrating leucocytes
during an inflammatory episode [53].
Unlike most chemokines, FKN is constitutively expressed
in the CNS with particularly high levels in hippocampal
neurons [34]. Astrocytes can also express FKN [33], although
at relatively lower levels than neurons, whereas microglia
appear not to express FKN mRNA transcripts. Hatori et al.
[33] also report that neurons and microglia express CX3CR1
mRNA, whereas astrocytes do not. Therefore, neurons and
astrocytes expressing FKN can signal to neurons and micro-
glial cell types possessing CX3CR1 receptors. In this way,
neurons may regulate microglial proliferation, because
exogenous FKN can increase the number of BrdU-labelled
microglia [33]. This may have implications in pathophysiolo-
gical insults, including stroke, where FKN is upregulated and
microglial numbers increase around the sites of neuronal
damage [54]. Thus, cross-communication between FKN-
expressing neurons and CX3CR1-containing microglia may
potentially be an important factor in many CNS-related path-
ologies. It is also likely, however, that the sustained high
levels of FKN in the brain throughout adulthood serve
normal physiological functions in addition to a rapid
response mechanism in times of traumatic injury.4. Activators and repressors of fractalkine
and CX3CR1 expression
Cleavage of the extreme N-terminal chemokine domain
releases soluble FKN which can function as a signalling mol-
ecule and activate CX3CR1 receptors on neighbouring cells.
FKN is constitutively expressed by certain neurons in the
CNS but its expression levels can also be increased by several
stimulators. For example, the treatment of rat aortic smooth
muscle cells (SMCs) with the pro-inflammatory cytokine,
TNF-a, induces the expression of FKN and CX3CR1 in a
nuclear factor kB (NF-kB)-dependent manner [55]. Moreover,
FKN itself can induce further FKN expression in a pertussis
toxin (PTX)-sensitive and G protein-dependent manner.
FKN autoregulation was shown to occur in this SMC type
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3-kinase (PI3K), phosphoinositide-dependent kinase 1 (PDK1),
Akt, NIK, IKK and NF-kB activation [55]. Whether these same
intracellular signalling cascades are recapitulated in CNS
neurons following TNF-a exposure remains to be confirmed.
FKN has been shown to inhibit lipopolysaccharide
(LPS)-induced TNF-a release from microglia [56], suggesting
anti-inflammatory actions of FKN. Interestingly, when mixed
neuron–glial cultures are prepared from CX3CR1 knockout
(CX3CR1
2/2) mice and stimulated with LPS, microglial cells
in these mixed cultures release a reduced amount of TNF-a,
nitric oxide (NO) and superoxide [57]. This suggests that the
CX3CR1 receptor is involved in the release of pro-
inflammatory substances from activated microglia. Therefore,
by disrupting ‘normal’ FKN/CX3CR1 communication, it seems
possible to switch the actions of FKN from anti-inflammatory to
pro-inflammatory in nature.
By contrast, astrocytes do not constitutively express
FKN protein. Astrocytes that are treatedwith certain pro-inflam-
matory cytokines such as TNF-a and IL-1b, however, upregulate
expression of FKN in a time-dependent manner. Treatment of
astrocytes with TNF-a induces FKN expression after 12 h and
levels peak at 24 h. IL-1b, on the other hand, increased FKN
expression much earlier after 2 h, peaking between 4 and 8 h
post-stimulation [58]. It appears, therefore, that FKN may be
upregulated in astrocytes in response to several pro-inflamma-
tory signals, which can occur in conditions such as stroke,
multiple sclerosis (MS) and Alzheimer’s disease (AD). This
increased expression of FKN could, in theory, modulate the
release of further pro-inflammatory stimuli from microglial cell
types, thus protecting susceptible neurons from neurotoxicity.
FKN upregulation and release in such neuroinflammatory
situations may, therefore, be neuroprotective and serve an
overall anti-inflammatory action in the CNS. In later sections,
however, we highlight some caveats when using FKN2/2 and
CX3CR1
2/2 mice to study whether FKN is neuroprotective or
neurodamaging. The use of knockout animals that have had
either FKN or CX3CR1 deleted from conception and allowed
mature to adulthood with disruption to the FKN/CX3CR1 com-
munication system can respond to FKN treatment differently to
wild-type animals following inflammatory and neurodegenera-
tive insults. Therefore, like many cytokines and chemokines
studied in recent years, FKN can be either anti-inflammatory
or neurodamaging depending on the context. The timing
of administration (i.e. pre- or post-insult) and the concentration of
FKN will be important factors in determining the response
of neurons to potentially neurotoxic injury.5. Fractalkine and CX3CR1-mediated
intracellular signalling in neurons
and microglia
The FKN receptor, CX3CR1, is reportedly expressed on micro-
glia and on neurons [33,39,45,58–64]. CX3CR1 is a seven
transmembrane domain receptor coupled to Gi and Gz sub-
types of G proteins [65], activation of which is linked to
several intracellular second messengers (figure 1) [55]. In
microglia, FKN has been shown to decrease LPS-induced
MHCII and CD40 mRNA levels in vitro. Moreover, microglial
IL-1b protein expression is also attenuated in cells treated
with FKN and these anti-inflammatory effects are Akt (alsoknown as PKB) and PI3-kinase-dependent [66]. FKN also
rapidly increases Akt activation in microglia in a dose- and
time-dependent manner, as measured by phosphorylation of
histone 2B. Astrocytes, on the other hand, do not demonstrate
this intracellular signalling cascade post-FKN exposure [58].
Several studies have also used in vitro cell culture systems
to investigate the effects of FKN on neuronal cell types. Treat-
ment of human neurons with FKN induced transient
phosphorylation of ERK1/2 within 1 min and Akt within
10 min of exposure [43]. The same authors also showed that
FKN can significantly inhibit NMDA-induced calcium
influx in neurons, and this effect is insensitive to PTX pre-
treatment. This attenuation of calcium influx is, however,
abolished by inhibition of ERK1/2 signalling. FKN also inhi-
bits NMDA-mediated apoptosis and this neuroprotective
effect is abolished by blocking Akt and ERK1/2 signalling
pathways [43]. This work demonstrates that FKN can have
direct effects on neurons and that these actions may promote
neuroprotection following potentially toxic insults.
It is important to differentiate between FKN’s direct effects
on neuronal cells versus glial cell-mediated neuromodulatory
effects. When hippocampal neurons are cultured with a glial
‘feeder layer’, a pure neuronal cell population can be achieved.
Treatment of a pure neuronal hippocampal culture with sol-
uble FKN activates ERK1/2, whereas no JNK or p38 MAPK
upregulation occurs. FKN also activates the transcription
factor, CREB, in hippocampal neurons [39]. Removal of this
glial feeder layer causes a 75% decrease in basal Akt phos-
phorylation in neurons. Subsequent treatment of these
neurons with FKN induces a significant increase in phospho-
Akt levels which is PI3-kinase-dependent [59]. Inhibiting
PI3-kinase activity in neurons abolishes FKN-mediated neuro-
protection. FKN also induces translocation of the p65 subunit
of NF-kB to the nucleus in hippocampal neurons and this is
prevented by a specific inhibitor of PI3-kinase, suggesting
that FKN activates NF-kB through Akt [59]. These results
give credence to a possible role of FKN inmodulating neuronal
synaptic plasticity as the transcription factors CREB andNF-kB
are intimately linked to complex temporal gene regulation
required for learning and memory [67].6. Fractalkine and CX3CR1 in CNS
development
During early postnatal development, neurons forge many
more synaptic connections than is necessary for normal adult
brain function. Consequently, a portion of these connections is
not maintained into adulthood but removed through a process
of activity-dependent pruning [68]. More recently, microglial
cells have been suggested to play a key role in developmental
synaptic pruning. Paolicelli et al. [69] report that microglia
actively phagocytose synapses during the first few weeks of
mouse brain maturation. Using CX3CR1
GFP/GFP mice, in
which microglia are fluorescently labelled (with green fluor-
escent protein, GFP) and the FKN receptor knocked out
(CX3CR1
2/2), they quantified the number of PSD-95-labelled
dendritic spines on CA1 neurons during the first five weeks of
postnatal development. They found that during the second–
third weeks, CX3CR1
2/2 mice possess more synapses than
wild-type mice. Interestingly, CX3CR1
2/2 mice also express
reduced numbers of microglia in the CA1 region of the hippo-
campus during weeks 2–4 of postnatal development. The
microglia
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Figure 1. Fractalkine and CX3CR1 expression and signalling. Fractalkine is a large chemokine molecule consisting of four major functional regions. These include an
N-terminal chemokine domain which can be cleaved by metalloproteinases such as ADAM10, TACE and the lysosomal cysteine protease, cathepsin S. The glycosylated
mucin-like stalk is thought to be involved in cell adhesion, with particular affinity for migrating leucocytes at sites of inflammation. Fractalkine also contains a
hydrophobic transmembrane region and intracellular C-terminal domain. Neuronally expressed membrane-bound and soluble cleaved fractalkine can bind to its
receptor, CX3CR1, which is G protein-coupled and transduces several well-characterized signalling pathways leading to activation of transcription factors, including
NF-kB and CREB. FKN, fractalkine; Gi, heterotrimeric G protein-coupled to Gi protein; PI3K, phosphatidylinositide 3-kinases; Ras, small GTPase; Raf, small GTPase;
PLC, phospholipase C; PKC, protein kinase C; Akt, serine/threonine-specific protein kinase; MEK, mitogen-activated protein kinase kinase; MEKK, MAP3kinase; p38,
p38 mitogen-activated protein kinase; IkB, inhibitor of kappa B; IKK, inhibitor of kappa B kinase; ERK, extracellular signal-regulated kinases; JNK, c-Jun N-terminal
kinase; NFkB, nuclear factor kappa B; CREB, cAMP response element-binding protein.
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act as a chemotropic agent to attract microglial cells into the
brain. Therefore, knocking out the CX3CR1 receptor would
render microglia blind to the attractive FKN cue and lead to
reduced numbers of microglia in the brain of CX3CR1
2/2
mice. If microglia are actively involved in synapse pruning at
this developmental stage, then a reduced number of microglial
cells could explain the higher density of synapses in the brains
of CX3CR1
2/2 mice [69]. However, an alternative explanation
might be that FKN/CX3CR1 signalling is required for propermicroglial-recognition of synaptic boutons before and/or
during engulfment and phagocytosis.
In contrast to the action on microglia, astrocytes show little
or no cell migratory response to FKN. Even activation of astro-
cytes with TNF-a or IL-1b does not induce a migratory
phenotype in response to FKN exposure. Moreover, Lauro
et al. [70] showed that neurons from the hippocampus and cer-
ebellum display reduced cell migration in in vitro assays in
response to FKN. This inhibitory effect of FKN on neuronal
cell migration was dependent on activation of the CX3CR1
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activity. The authors suggest that FKN may inhibit neuronal
cell migration by increasing binding and adhesion to laminin,
a component of the extracellularmatrix [70]. Interestingly, FKN
has the opposite effect on microglial cells and decreases their
adhesion to poly-L-lysine-coated surfaces in in vitro assays.
Blocking the CX3CR1 receptor and inhibiting Gi protein-
coupled responses with PTX diminishes microglial migration
in response to FKN [58]. This supports the hypothesis that
FKN may act as an attractive microglial guidance cue during
development in vivo and that FKN/CX3CR1 signalling
promotes the population of CNS tissue with peripherally
derived cell types.
In the developing barrel field of the somatosensory
cortex, FKN/CX3CR1 signalling is also thought to regulate
microglial influx, and population of sites where developing
thalamocortical synapses are concentrated (i.e. barrel centres).
Hoshiko et al. [71] showed that microglial cell infiltration into
the barrel centres occurs around postnatal day 5 (P5) in the
mouse; at a time when FKN is abundantly expressed in
these regions. In CX3CR1
GFP/GFP receptor knockout mice,
microglial entry into the barrel centres is delayed by a few
days, but is indistinguishable fromwild-typemice at postnatal
day 9 (P9). The absence of CX3CR1 also delays the maturation
of functional glutamate receptors evidenced by the fact that
the AMPAR/NMDAR ratio at P9 was significantly lower in
CX3CR1
2/2 than in CX3CR1
þ/2mice.Moreover, the develop-
mental switch from GluN2B to GluN2A-containing NMDA
receptors that is known to occur between the first and second
postnatal weeks in the thalamocortical area of the mouse was
delayed in CX3CR1
2/2 mice but this delay was only transient
[71]. This lends support to the notion that microglia influence
synaptic maturation during development and that FKN
signalling contributes to this process.
In the adult brain, neuronally derived FKN is thought to
maintain microglia in a quiescent state. Lyons et al. [66] have
shown that in aged rats, the levels of FKN in the hippocampus
decrease and this correlates with an increase in CX3CR1
expression and microglial cell activation as evidenced by
increased MHCII, CD40 mRNA and IL-1b protein levels.
Thus, FKN may play a role in the homeostatic suppression of
microglial activation. The seemingly natural decline in neuron-
ally expressed FKN in the hippocampus of aged animals [66]
might contribute to increased microglial activation. If the same
occurs in humans, this decrease in FKN expression over time
could contribute to several cognitive and neurodegenerative
disorders that are more common in the elderly.7. Fractalkine and CX3CR1 modulate
synaptic plasticity
FKN mRNA and protein levels are abundant in the uninjured
adult hippocampus, an observation that prompted some to
investigate if FKN plays a physiological role in learning and
memory formation. Many recent publications suggest a func-
tional role for both FKN and CX3CR1 in the regulation
of neurotransmission and synaptic plasticity [72–76]. There
still exists some controversy as to whether CX3CR1 receptors
are present on neurons in vivo; even though several papers
have reported that CX3CR1 does, indeed, reside on neurons,
particularly hippocampal neurons [45,59]. Meucci et al. [39]
reported that FKN induces calcium influx in pure hippocampalneuronal culture in vitro in the absence of any microglial
contamination. Heinisch & Kirby [64] also have shown that
CX3CR1 localizes to the perinuclear region of serotonergic
(5-HT) neurons in the raphe in vivo in addition to exhibiting
microglial expression.
As discussed above, there is mounting evidence that FKN
exerts direct actions on neurons through the CX3CR1 receptor.
For instance, FKN reduces spontaneous glutamate release and
post-synaptic glutamate currents [39,45]; the latter being linked
to dephosphorylation of the GluR1 AMPA receptor subunit
[73]. FKN also decreases the frequency, but not the amplitude,
of spontaneous mini excitatory post-synaptic currents
(mEPSCs) from hippocampal neurons in culture [39]. Several
lines of evidence indicate that the predominantly inhibitory
action of FKN in the hippocampus may underlie an important
role in synaptic scaling, and homeostasis of the hippocampal
network that is necessary for memory-associated synaptic
plasticity [72,74,77]. For example, FKN causes a reversible
decrease in field excitatory post-synaptic potentials (fEPSPs)
in the CA1 region of mouse hippocampal slices. This
depression is rapid in onset and dose-dependent but reversible,
as the fEPSP amplitude recovers within 30 min of FKN wash-
out [72]. This depression of fEPSPs is absent in CX3CR1
2/2
mice. Similarly, FKN causes a significant reduction in EPSCs
from stimulated CA1 pyramidal neurons [73]. The ability of
FKN to depress EPSCs appears to be post-synaptically
mediated, because paired-pulse facilitation (PPF) is unaltered
following FKN treatment. Moreover, EPSC depression is
absent in CX3CR1
2/2 mice. FKN’s depressive actions on
EPSCs are dependent on calcium entry into the cell but inde-
pendent of NMDA receptor activation [73]. FKN inhibits
forskolin-induced Ser845 phosphorylation of the GluR1 sub-
unit of the AMPA receptor which contributes to inhibition of
EPSC amplitude. Interestingly, FKN does not induce EPSC
depression when the baseline synaptic stimulation protocol
was suspended until after FKN washout, indicating that
FKN-mediated depression is activity-dependent. FKN reduces
AMPA receptor currents and the larger the current amplitude,
the greater is the depression by FKN [73]. Taken together, these
pieces of evidence suggest that FKN modulates AMPA recep-
tors at active glutamatergic synapses and depresses synaptic
transmission. Interestingly, prior induction of long-term
depression abolishes the inhibitory effect of FKN on synaptic
transmission arguing that these forms of synaptic depression
may overlap at the molecular level [72].
Interestingly, there seems to be an important temporal
component to the inhibitory actions of FKN on long-term
potentiation (LTP). FKN, when present in the circulating per-
fusate prior to high-frequency stimulation (HFS), inhibits LTP
in the CA1 region of acute hippocampal slices. When added
just a few minutes after LTP induction, however, FKN has no
dampening effect on the maintenance phase of LTP [78]. This
inhibitory action of FKN on LTP is mediated through the
CX3CR1 receptor because it was absent in CX3CR1
2/2 mice.
There is also evidence to suggest that adenosine and ade-
nosine receptors are modulated by FKN activity in the
hippocampus. FKN has been shown to cause the release of
adenosine from microglia [79]. Exposure of acute hippocam-
pal slices to a broad spectrum adenosine receptor antagonist
abolished the inhibitory effect of FKN on LTP. Maggi et al.
[78] pinpointed the A3R adenosine receptor as the crucial
subtype mediating inhibition of LTP by FKN in the CA1.
This is in contrast to FKN-mediated neuroprotection which
rsob.royalsocietypublishing.org
Open
Biol3:130181
6
 on February 18, 2016http://rsob.royalsocietypublishing.org/Downloaded from appears to be dependent on adenosine-1 receptor (A1R) acti-
vation [79]. In agreement with this study, the same group
showed that FKN does not induce EPSC depression in
A3R
2/2 mice, but that this feature is present in both A1R
2/2
and/or A2AR
2/2 mice [74]. More recently, they also showed
that FKN potentiates the NMDA receptor component of the
fEPSP in the hippocampal CA1 region [80]. The authors pro-
pose that FKN activates CX3CR1 receptors on microglia
which induces adenosine release. This adenosine may, in
turn, activate A2AR receptors on microglia (and possibly astro-
cytes) causing the release of D-serine which acts as a co-agonist
at the NMDA receptor, thus potentiating NMDA-mediated
fEPSPs. Interestingly, this might explain why FKN inhibits
LTP when administered prior to LTP induction but not if
added just a few minutes post-HFS. The increase in intracellu-
lar calcium that accompanies NMDA fEPSP potentiation by
FKN may disrupt LTP induction which has been shown to
depend on the duration and amplitude of Ca2þ elevations as
well as the metaplastic activation state of the NMDA receptors
involved [81,82].
CX3CR1
2/2 and CX3CR1
þ/2 mice display deficits
inmotor learning as assessed by standard rotarod training tech-
niques. There is, however, no difference between CX3CR1
2/2,
CX3CR1
þ/2 and wild-type mice in spontaneous locomotor
activity as assessed by the open field test. Similarly,
CX3CR1
2/2 and CX3CR1
þ/2 mice were no more anxious
than control mice as assessed by the elevated plus maze [76].
Using standard fear-conditioning paradigms, CX3CR1
2/2
and CX3CR1
þ/2 mice were assessed for deficits in associa-
tive learning and memory. During the training period,
CX3CR1
2/2 and CX3CR1
þ/2 mice displayed similar freezing
behaviour to wild-type mice. When the mice were placed
back into the chamber 24 h later, however, CX3CR1
2/2 and
CX3CR1
þ/2 mice displayed a reduction in their freezing
behaviour. This ‘context-specific’ type of associative memory
is thought to be predominantly hippocampal-dependent. Inter-
estingly, when the CX3CR1
2/2 and CX3CR1
þ/2 mice were
placed into a novel environment and exposed to the condition-
ing stimulus, the animals froze for the same amount of time as
their wild-type counterparts [76]. This ‘conditioning-specific’
type of associative memory is thought to depend on both the
hippocampus and amygdala suggesting that CX3CR1
2/2
and CX3CR1
þ/2 mice may display hippocampal-specific
deficits in cognition. In agreement with this notion is the fact
that CX3CR1
2/2 and CX3CR1
þ/2 mice perform worse in
probe trials of the hidden water maze task—a hippocampal-
dependent memory paradigm. Rogers et al. [76] also looked
at measures of synaptic plasticity in CX3CR1
2/2 and
CX3CR1
þ/2 mice. Basal synaptic transmission as well as PPF
in the hippocampus was normal. However, CX3CR1
2/2 and
CX3CR1
þ/2 mice showed a reduction in LTP in the CA1 stra-
tum radiatum. This may be explained by the higher basal
levels of IL-1b in the hippocampus of CX3CR1
2/2 and
CX3CR1þ/2 mice compared with wild-type. The origin of
this excess IL-1b may be microglial cells, because CX3CR1
2/2
mice possess more activated microglia in the hippocampus.
Treating hippocampal slices with IL-1 receptor antagonist (IL-
1RA) rescued the deficits in LTP seen in CX3CR1
2/2 mice.
Moreover, treating CX3CR1
2/2 mice with IL-1RA reverses
the deficits in learning and memory seen in contextual fear-
conditioning and water maze spatial memory training. TNF-a
levels were also elevated in the cerebellum of CX3CR1
2/2
mice suggesting an overall increase in inflammatory-associatedprotein levels in the brains of CX3CR1
2/2 and CX3CR1
þ/2
mice [76].
Taken together, there is substantial evidence that FKN
and CX3CR1 signalling play several crucial roles in synaptic
plasticity, learning and memory and FKN likely contributes
to maintaining proper homeostasis of synaptic transmission
in the hippocampus (figure 2).8. Fractalkine and CX3CR1 role
in neurogenesis
Hippocampal neurogenesis is often correlated with cognitive
function [83,84] and new-born dentate granule cells are thought
to be involved in spatial memory formation [85,86]. Both
CX3CR1
2/2 andCX3CR1
þ/2mice display reduced hippocam-
pal neurogenesis compared with wild-type controls [76,87].
Moreover, blocking CX3CR1 activity in young adult rats
(three months old) results in an attenuation of neurogenesis.
Given the role of hippocampal neurogenesis in learning and
memory, reduced neurogenic rate may underlie impairments
observed in CX3CR1
2/2 mice in hippocampal-dependent
memory tasks.
It is widely accepted that cognitive ability decreases with
age and this decline correlates with reduced levels of hippo-
campal neurogenesis. Interestingly, treatment of older animals
with exogenous FKN reverses this age-related decrease in
hippocampal neurogenesis [87]. In support of the observation
that FKN limits pro-inflammatory cytokine release in the hippo-
campus, Bachstetter et al. [87] showed that administering an
IL-1 receptor antagonist (IL-1RA) attenuated the decrease
in hippocampal neurogenesis which occurs as a result of
blocking CX3CR1 receptors. This suggests that FKN may acti-
vate CX3CR1 on microglial cells to attenuate IL-1b release to
maintain the rate of hippocampal neurogenesis.9. Fractalkine and CX3CR1 mediate
neuroprotection
Aswell as serving to inhibit over-activation of the hippocampal
network under physiological conditions, FKNmay also act as a
first-line defence response to neuronal injury and neuroinflam-
mation. Pathological levels of glutamate and excitotoxicity can
lead to a TACE-mediated increase in soluble FKN, thus limiting
neuronal damage [45,51,73, 88,89]. As well as attenuating glu-
tamate-mediated excitation, FKN can enhance the
responsiveness of at least some neurons to GABA inhibition.
Specifically, FKN inhibits serotonin neurons of the raphe by
enhancing the activity of GABAergic receptors [64]. In fact,
over 70% of raphe serotonin neurons exhibit FKN/CX3CR1
co-localization further suggesting that FKN has direct actions
on neurons as opposed to indirect actions through microglial-
mediated neuromodulation. If the direct actions of FKN on
GABA-sensitivity are exclusive to serotonin-containing neur-
ons in the dorsal raphe nucleus, then this mechanism
presents a novel drug target for mood-related disorders such
as anxiety and depression. However, a recent study by Roseti
et al. [90] suggests that FKNmay also modulate GABAA recep-
tor-mediated currents in other brain regions, such as the
hippocampus and cortex, and that this action has relevance
for disorders such as mesial temporal lobe epilepsy.
CX3CR1FKN
microglia
adenosine
d-serine
A2AR
GABAAR
NMDA
Cl–
Ca2+
microglia
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+
nucleus
NF-kB
CREB
LTP
Ca2+GLUT
A3R
IL-1R
IL-1
TNF
IL-6
A1R
post-synaptic
neuron
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neuroprotection
CAMKII
Figure 2. Fractalkine and CX3CR1 in synaptic plasticity, neurogenesis and neuroprotection. Schematic diagram describing several mechanisms of action of fractalkine
(FKN) in modulating neuronal function. Hippocampal neurons, in particular, express high levels of FKN and CX3CR1 receptors. Microglia also possess CX3CR1 and can
release several chemicals that modulate neurotransmission and synaptic plasticity. First, FKN acting through CX3CR1 modulates AMPA receptor phosphorylation
leading to increased calcium (Ca2þ) entry and inhibition of both excitatory post-synaptic potentials (EPSPs) and long-term potentiation (LTP). FKN can also increase
inhibitory post-synaptic currents (IPSCs), possibly by enhancing neuronal responsiveness to GABA-mediated chloride entry. How FKN enhances IPSCs remains
unknown, but this may be due to FKN activating CX3CR1 on microglia and causing the release of adenosine. This, in turn, could activate A3R receptors on neurons,
kick-starting a signalling cascade which results in modulation of GABAA receptors to increase their sensitivity to GABA. Adenosine may also activate A2AR on micro-
glial cells and induce the release of D-serine which acts as a co-agonist at the NMDA receptor leading to increased calcium entry. In this way, FKN may also inhibit
LTP induction and modulate synaptic plasticity. The adenosine released by microglia has also been suggested to play a role in neuroprotection by activating A1R
receptor subtypes on neurons. Finally, FKN may play a role in hippocampal neurogenesis by inhibiting the release of IL-1b from microglial cell types. Much of this
schematic diagram is speculative and based on our limited current knowledge of the interplay between FKN and CX3CR1 in CNS neurotransmission. There is still
much work to be done to dissect the signalling cascades involved in FKN-mediated neuromodulation.
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microglia-mediated neurotoxicity
Microglial cells are the resident macrophages of the brain and
are activated in response to neuronal injury [91]. Cardona
et al. [92] made use of the CX3CR1
GFP/GFP receptor knockout
mouse to study the role of FKN and CX3CR1 signalling in sev-
eral models of microglial-induced neurotoxicity. CX3CR1
2/2
mice demonstrated significantly greater microglial activation
in response to intraperitoneal (i.p.) administration of LPS.
As only microglial cells are labelled with GFP in these
CX3CR1
2/2 mice, Cardona et al. developed an adoptivetransfer technique that allowed them inject LPS-activated
microglial cells, deficient in CX3CR1 receptors, into the brains
of wild-type animals. The ‘behaviours’ of these GFP-labelled
microglial cells were compared with those taken from
CX3CR1
þ/2 mice. Interestingly, CX3CR1
þ/2 microglial cells
migrated far from the site of injection and seemed to preferen-
tially invade white matter tracts of the CNS parenchyma.
CX3CR1
2/2 microglia, however, localized to the site of injec-
tion in the frontal cortex of wild-type mice. Moreover, there
was significantly more neuronal cell loss surrounding acti-
vated GFPþ microglia transplanted from CX3CR12/2 mice
than in wild-type brains that received CX3CR1
þ/2 microglial
cells. The authors attributed this increased neuronal cell
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photoxin or IL-6) from CX3CR1
2/2 microglia upon LPS
stimulation. Indeed, when IL-1RA (IL-1 receptor antagonist)
was added along with the adoptive transfer microglia, neuro-
nal cell death was reduced significantly and IL-1RA seemed
to restore the migratory activity of CX3CR1
2/2 cells from the
site of injection.
Cardona et al. [92] also evaluated the role of FKN/CX3CR1
signalling in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine
(MPTP)-induced neurodegenerative mouse model of Parkin-
son’s disease (PD). Dopaminergic cell death in the substantia
nigra pars compacta of MPTP-injected CX3CR1
2/2 mice was
significantly more substantial than that seen in wild-type
mice. Moreover, FKN knockout (CX3CL1
2/2) mice displayed
similar enhancement of neuronal loss to CX3CR1
2/2 mice
indicating that it is the perturbation of FKN-mediated modu-
lation of microglial activity that worsens neuronal cell death,
i.e. neuron–microglia crosstalk, rather than a specific loss of
either FKN or its receptor. Pabon et al. [89] showed that FKN
was neuroprotective in the 6-hydroxydopamine (6-OHDA)
toxin-induced rat model of PD. In this model, 6-OHDA is
infused in the striatum of rats causing selective neurotoxicity
of dopaminergic neurons, thus mimicking the human form of
PD. Microglial activation is thought to contribute to neuro-
degeneration which follows 6-OHDA administration. FKN
infused into the rat striatum over the course of several weeks
caused a significant reduction in microglial activation which
correlated with marked neuroprotection of dopaminergic
neurons [89].
Activation of microglial cells with LPS can convert the
phenotype of microglial cells from a resting state into a pha-
gocytic and neurotoxic form. Zujovic et al. [56] showed that
microglia that were pre-exposed to LPS in vitro and sub-
sequently added to a hippocampal neuronal culture were
neurotoxic and caused 20% neuronal cell death. LPS induced
the release of TNF-a from microglia which FKN treatment
partially blocked. The addition of a neutralizing antibody
against endogenous FKN enhanced neuronal cell death in
this co-culture of LPS-activated microglia. These results
suggest that tonic activation of CX3CR1 by endogenous
FKN may serve as an anti-inflammatory signal that maintains
microglial cells in a quiescent state. Mizuno et al. [93] showed
that microglia which are activated by both LPS and inter-
feron-gamma (IFN-g) release NO, interleukin (IL)-6 and
TNF-a. FKN dose-dependently inhibits neuronal cell death
induced by activated microglia suggesting an intrinsic role
for the high levels of FKN expressed on neurons in the
adult CNS [93].11. Fractalkine and CX3CR1 in ischaemic
brain injury
Despite the evidence of a neuroprotective role for FKN pre-
sented above, there are data suggesting this chemokine is
detrimental in some settings. Soriano et al. [94] generated
mice that were deficient in FKN (CX3CL1
2/2) in order to
determine the role of FKN in ischaemic brain injury. They
induced a transient focal cerebral ischaemia (2 h) and allowed
a 22 h reperfusion of the middle cerebral artery before sacrifi-
cing the mice for histological analysis of tissue injury.
Twenty-four per cent of the wild-type mice died in this
22 h period, whereas none of the 20 CX3CL1
2/2 mice died.Moreover, there was a 28% reduction in the size of the
ischaemic infarct in CX3CL1
2/2 mice correlating well with
the reduced mortality rate. This study suggests that FKN
expression is detrimental to recovery post-ischaemic injury
[94]. Cipriani et al. [95] performed a similar study on
CX3CL1
2/2 mice and also CX3CR1
2/2 mice. They also
found that CX3CL1
2/2 mice possessed a smaller ischaemic
infarction following middle cerebral arterial occlusion
(MCAO) and interestingly, so did CX3CR1
2/2 mice.
Counterintuitively, Cipriani et al. also showed that adminis-
tration of exogenous FKN slightly before MCAO to wild-
type mice reduced the volume of the subsequent ischaemic
infarct. Therefore, FKN is neuroprotective in wild-type mice
that receive an ischaemic insult. Exogenous FKN adminis-
tration had no effect in CX3CR1
2/2 mice but did, however,
increase the size of the infarct seen in CX3CL1
2/2 mice.
Therefore, mice that develop to adulthood with normal
levels of FKN present in the brain (i.e. wild-types), respond
favourably to FKN pre-treatment post-ischaemia. The story
is further complicated, because exogenous FKN treatment is
only beneficial at a reasonably narrow concentration range
of between 15 and 70 pM; greater than 150 pM FKN becomes
harmful in wild-types post-ischaemia. Interestingly, the neu-
roprotective effects of exogenously applied FKN were lost in
A1R2/2 knockout mice [95].
The fact that a developmentally disrupted neuron–
microglia communication system can alter whether FKN is
protective or detrimental in ischaemic injury suggests that
FKN/CX3CR1 signalling in microglia is important for their
proper functioning. Under in vitro conditions that mimic an
in vivo MCAO injury, i.e. oxygen–glucose deprivation, FKN
caused a reduction in TNF-a release from microglia that were
cultured from CX3CL1
2/2 mice. Recently, a neuroprotective
role for TNF-a in ischaemic brain injury has been described
[96] and this may explain why exogenous FKN exacerbates
the infarct volume in CX3CL1
2/2 mice. The release of various
factors from microglia at the site of injury can have both posi-
tive and negative effects on neuronal survival and normal
microglia functioning appears disrupted in CX3CL1
2/2
mice, because FKN does not alter TNF-a release from wild-
type microglia. De´nes et al. [97] suggest that CX3CR1 is crucial
for maintaining proper microglial functioning in the CNS.
They also showed that the infarct size post-MCAO was signifi-
cantly reduced in CX3CR1
2/2mice comparedwithwild-types
and heterozygotes. Interestingly, they noted increased IL-1b
expression in CX3CR1
þ/2 mice compared with knockouts, but
the IL-1bwas not associated with microglial cell types. Instead,
astrocytes inCX3CR1
þ/2miceproducedelevated levelsof IL-1b
post-MCAO compared with knockout animals. This suggests
that astrocytes, under certain conditions, may also express
CX3CR1 receptors (figure 3) or, alternatively, thatmicroglia lack-
ing the CX3CR1 receptor assume a phenotype that can alter
astrocytic function in times of stress such as an ischaemic event.
Amore recent study by Pimentel-Coelho et al. [98] looked at
sex-specific effects of FKN and CX3CR1 in a neonatal model of
ischaemic-hypoxic injury. Three-day-old (P3) mice (male and
female) were subjected to MCAO followed by a 40 min 8%
oxygen challenge. They found that FKN mRNA levels are
reduced in the CA3 and CA1 of the hippocampus, in both
males and females, 24 h and 3 days post-ischaemia–hypoxia
and this reduction in FKN mRNA was evident up to five
weeks post-surgery. Twelve weeks post-ischaemia–hypoxia,
wild-type and CX3CR12/2 mice were tested for spatial
normal CNS physiology pathophysiology (e.g. ischaemia)
no inflammation
neuron
FKNastrocyte
microglia
injury-induced release of:
— pro-inflammatory cytokines
— excess glutamate
cathepsin S
TACE
cleavage of fractalkine
chemokine domain
fractalkine expression
on neurons and 
astrocytes
microglial activation
and infiltration
— reactive oxygen species
CX3CR1
Figure 3. Fractalkine and CX3CR1 in neuroinflammatory conditions. In the uninjured brain under normal physiological conditions, fractalkine (FKN) is largely
expressed on neurons and CX3CR1 receptors on microglial cells. FKN sequesters microglia in a quiescent ‘inactive’ state. Astrocytes are relatively devoid of FKN
and CX3CR1 protein expression. Under a pathological insult, such as occurs following ischaemia, FKN can be upregulated on neuronal cells. FKN can also be cleaved
by the metalloproteinase, TNFa-converting enzyme (TACE), and lysosomal cysteine protease, cathepsin S, released during injury. Upregulated levels of FKN can
attract microglia to the site of inflammation, where they become activated and release pro-inflammatory mediators such as cytokines, reactive oxygen species
(ROS) and glutamate. Astrocytes can also express FKN following an inflammatory insult and thus can communicate with both neurons and microglia via
CX3CR1. The increased expression of FKN should have a net anti-inflammatory action and serve to limit inflammation in favour of functional recovery of CNS tissue.
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task. CX3CR12/2 males subjected to neonatal ischaemia–
hypoxia showed similar test scores to sham-operated
CX3CR12/2males. Sham-operated CX3CR12/2 females, how-
ever, performed better than their ischaemia–hypoxia-subjected
counterparts [98]. This can be explained by the reduced levels
of neuronal injury in wild-type females compared with
CX3CR12/2 females post-neonatal ischaemia–hypoxia.
Therefore, CX3CR1 signalling seems to play a greater neuro-
protective role in female compared with male mice following a
neonatal ischaemic-hypoxic event.12. Fractalkine and CX3CR1 in multiple
sclerosis
The FKN/CX3CR1 signalling partnership may have a role to
play in neuroinflammatory and autoimmune diseases of the
CNS. MS is perhaps the quintessential autoimmune disorder
of the CNS, characterized by inflammation and demyelinat-
ing lesions in the spinal cord and brain of affected patients
[99,100]. The animal model that is regarded to most closely
model the human disease is experimental autoimmune ence-
phalomyelitis (EAE) [101,102]. Expression levels of FKN
and CX3CR1 receptor have been found to change in and
around the demyelinating lesions that accompany EAE and
disease progression. Myelin oligodendrocyte glycoprotein(MOG)-induced EAE in rats causes a marked accumulation
of CX3CR1-expressing microglia within brain lesions and
sites of inflammation [103]. Notably, CX3CR1 mRNA
increased in the periplaque regions of the CNS as well in
early-active, late-active and also inactive demyelinated lesions,
indicating the infiltration of microglia into these affected areas.
Neuronal FKN levels in the same rats remained at control
levels, but there was an increase in astrocyte-associated FKN
expression at sites of inflammation. This is particularly inter-
esting as it suggests that activated astrocytes may be
involved in attracting microglia to the sites of inflammation
through the upregulation of FKN on their surface membranes
[103]. Neuronal FKN mRNA expression in the brains of rats
induced with EAE is unaltered [104]. However, immuno-
deficient a-myelin basic protein T-cell receptor transgenic
mice that develop EAE spontaneously display upregulated
FKN in brain microglia. Similarly, mice actively immunized
with proteolytic peptide show increased expression of FKN
in brain microglia [105]. In this regard, autoimmune dysfunc-
tion in the CNS may be a trigger for microglia themselves to
upregulate FKN expression. This may contribute to disease
progression, or more likely, be a mechanism by which micro-
glia attempt to autoregulate their over-activation and return
neighbouring microglia to a quiescent state.
In a recent study by Garcia et al. [106], the authors found
that the disruption in FKN signalling that occurs on peripheral
bone-marrow-derived cells in CX3CR1
2/2 mice contributes to
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2/2 mice immu-
nized with MOG35–55 peptide displayed earlier onset and
more severe EAE symptoms than wild-type animals. The
same was true when EAE was induced by adoptive transfer
of MOG35–55 reactive T cells. CX3CR1
2/2 mice induced with
EAE showed an accumulation of CD115þLy6C–CD11cþ den-
dritic cells in the brain and this correlated with more
pronounced demyelination as well as enhanced neuronal
damage. CX3CR1
2/2 mice suffering from EAE also showed
over-expression of pro-inflammatory cytokines in CNS tissues.
TNF-a levels in EAE-affected CX3CR1
2/2 mice were higher
than their diseased wild-type counterparts. Likewise, IFN-g
mRNA was higher in the cerebellum and spinal cord and IL-
17 was more abundant in forebrain and cerebellar regions of
CX3CR1
2/2 mice induced with EAE. By contrast, levels of the
anti-inflammatory cytokine, IL-10, was significantly higher in
the spinal cord of EAE-wild-type mice comparedwith diseased
CX3CR1
2/2 animals [106]. Taken together, these results high-
light the importance of proper FKN/CX3CR1 signalling in
regulation of autoimmune responses and the possible role of
CX3CR1 in MS in the human population. In particular, poly-
morphic variants of the CX3CR1 receptor which can affect
FKN binding affinity as well as receptor expression have been
identified. A study by Stojkovic´ et al. [107] suggests that there
is a lower incidence of the CX3CR1I249/T280 haplotype in
patients that display secondary-progressive MS compared
with patients in the relapsing–remitting phase of the disease.
This genetic study reveals a possible protective effect of the
reference I249 allele on secondary-progressive MS when
linked with the T280 allele [107].13. Fractalkine and CX3CR1 in
spinal cord injury
Spinal cord injury (SCI) induces a devastating trauma to
neuronal cells and results in the destruction and severing of
axons, leading to widespread neurodegeneration and inflam-
mation in and around the site of injury [108]. After some
time, microglial cells and monocyte-derived macrophages
(MDMs) are recruited to the affected regions of the spinal
cord [109]. Their role is presumably to promote functional
recovery of damaged nervous tissue. They may, however,
promote the formation of a glial scar which, in actuality,
serves to inhibit functional recovery of damaged neuronal
connections in favour of speeding up the healing process
and increasing the chance of survival of the whole organism
[110]. Donnelly et al. [111] have shown that CX3CR1
2/2 mice,
lacking the receptor for FKN, display a distinct repertoire of
MDMs that infiltrate the injured spinal cord compared with
wild-type mice. CX3CR1
2/2 mice expressed relatively greater
numbers of CCR2þ CNS macrophages post-SCI than wild-
type mice, whereas wild-type animals displayed more iNOSþ
MDMs in the injured spinal cord. CX3CR1
2/2 microglia also
produced less IL-6 and iNOS mRNA post-SCI. Moreover,
functional recovery after SCI in CX3CR1
2/2 mice was more
rapid and sustained, implicating the importance of neuron/
microglial signalling in neuronal regeneration. Therefore, in
SCIs, microglia expressing the CX3CR1 receptor may release
more substances that activate astrocytes and promote glial
scar formation in favour of the alternative scenario which
would be to promote functional regeneration of neuronal
axons. Inhibiting CX3CR1 receptors at the correct temporalwindow post-SCI may, therefore, serve as a novel drug target
to promote neuroregeneration and inhibit microglial activation.14. Fractalkine and CX3CR1 in
Alzheimer’s disease
AD is a devastating progressive neurodegenerative condition
that mainly affects the elderly population and is characterized
by alterations in behaviour and cognitive impairment [112].
The classic hallmark of AD is extracellular plaques of mis-
folded amyloid-b (Ab) protein and neurofibrillary tangles
that either contribute to or are a consequence of neurodegen-
eration [113]. The brains of AD patients often show increased
activation of microglial cells around Ab plaques [114,115].
The natural aging process is also associated with decreased
expression of neuronal FKN levels [66] which may contribute
to excess microglial activation in the elderly. Neurons cul-
tured in the absence of microglial cells show resistance to
Ab-induced neurotoxicity [116]. Fuhrmann et al. [117] inves-
tigated the role of CX3CR1 signalling in the neurotoxic effects
of microglia in a triple-transgenic mouse model of AD. This
mouse model displays neuronal loss in layer III of the
cortex between four and six months of age. Knocking down
CX3CR1 in these mice rescued this neuronal loss suggesting
that microglia play a role in Ab-induced neuronal death.
There were a greater number of microglia around the areas
of neuronal damage and this increase in microglial density
preceded neuronal loss indicating that microglia are involved
in the elimination process. In triple-transgenic mice that also
had the CX3CR1 receptor knocked out, there was no increase
in microglial cell densities during this period. Microglial
migration velocity to the site of neuronal damage was two-
fold greater than in healthy areas of the cortex in both
transgenic mice and in CX3CR1
2/2 triple-transgenics. Once
neuronal elimination was complete, however, microglial
migration to the site of damage halted [117]. These observations
suggest that FKN/CX3CR1 signalling in microglia during
Ab-induced neuronal stress is detrimental to neuronal survival.
Wu et al. [118] microinjected Ab1240 fibrils into the CA1
region of the hippocampus and measured increased CX3CR1
mRNA and protein levels, whereas FKN protein expression
remained unchanged. Injecting siRNA against CX3CR1 along
with Ab1240 fibrils not only downregulated CX3CR1 protein
levels, but also CD11b expression. Moreover, CX3CR1 siRNA
attenuates Ab1240-induced IL-1b release from microglia.
Presumably, this IL-1b release from activated microglia con-
tributes to the impaired LTP measured in the CA1 of rats
treated with Ab1–40 fibrils. Suppression of CX3CR1 signalling
using siRNA rescues LTP expression in Ab1–40-treated rats.
Moreover, CX3CR1 siRNAalso rescues spatialmemory impair-
ments in Ab1–40-treated rats subjected to the Morris water
maze task [118].
It is widely accepted that AD is associated with chronic
inflammation which may contribute to disease aetiology
and pathogenesis [119]. Targeting the CX3CR1 receptor
early in AD may prove a fruitful drug-targeting strategy in
the future. Duan et al. [120] assessed the levels of several
chemokines at different ages in transgenic mice that develop
AD-like pathology in the brain. MIP-1a levels in the hippo-
campus and cerebral cortex of Tg2576 mice remained the
same as control at nine and 17 months of age. FKN
expression, on the other hand, decreased in both brain
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mice. Moreover, intense CXCL10 staining co-localized with
Ab-positive plaques in the brains of transgenic animals. It
is not known whether the decrease in FKN expression pre-
cedes or is a consequence of Ab plaque formation. Several
chemokines are present at high constitutive levels in the
brain throughout life, and alterations in the expression of
one can have downstream effects changing the levels of
other chemokines. Neuronal FKN expression decreases with
age [66] which may have knock-on effects on the levels of
other chemokines. Therefore, preventing this natural decrease
of FKN with age may represent a novel therapeutic target in
the fight against AD and related dementias.Biol3:13018115. Conclusion
The FKN/CX3CR1 ligand/receptor pair seems to have evolved
as a communication link between neurons andmicroglial cells.
Moreover, astrocytes, in the times of inflammation, seem toupregulate FKN which also allows them to talk to microglia
and neurons via CX3CR1 receptors. Overall, FKN appears to
impart anti-inflammatory effects during neuroinflammatory
events, such as stroke. This represents a novel neurotherapeutic
target for such conditions. As with all cytokines and chemo-
kines, however, it appears that the concentration and timing
of administration will be crucial to maximize neuroprotection
and prevent further toxicity to the system. FKN may also
have an important role in normal learning and memory
because it is expressed at such high levels on hippocampal
neurons, in particular. High exogenous levels of FKN appear
to have a dampening effect on synaptic transmission and
LTP, which is activity-dependent. FKN, therefore, may func-
tion to limit over-activation of the hippocampal formation
and maintain homeostasis in the neuronal network as a
whole. The natural decrease of FKN in the hippocampus
with age correlates with cognitive decline seen in older ani-
mals. Thus, preventing this downregulation of FKN may also
represent a novel therapeutic target in the fight against AD
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